Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 24, 2024

Combining Anti-VEGF and Anti-EGFR Antibodies: Irinotecan and Cetuximab With or Without Ramucirumab as a Second-Line Treatment for Colorectal Cancer

Journal of the National Cancer Institute

 

Additional Info

Journal of the National Cancer Institute
Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208)
J. Natl. Cancer Inst 2024 Sep 01;116(9)1487-1494, HS Hochster, P Catalano, M Weitz, EP Mitchell, D Cohen, PJ O'Dwyer, BA Faller, JS Kortmansky, MH O'Hara, SM Kricher, J Lacy, HJ Lenz, U Verma, AB Benson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading